PNC Financial Services Group Inc. Acquires New Shares in MaxCyte, Inc. (NASDAQ:MXCT)

PNC Financial Services Group Inc. acquired a new stake in MaxCyte, Inc. (NASDAQ:MXCTFree Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 6,255 shares of the company’s stock, valued at approximately $29,000.

A number of other hedge funds have also bought and sold shares of MXCT. Nisa Investment Advisors LLC grew its stake in MaxCyte by 47,100.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 11,800 shares of the company’s stock valued at $55,000 after buying an additional 11,775 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of MaxCyte by 350.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock valued at $56,000 after purchasing an additional 9,323 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of MaxCyte by 23.0% during the 4th quarter. Victory Capital Management Inc. now owns 12,316 shares of the company’s stock valued at $58,000 after purchasing an additional 2,306 shares in the last quarter. AJOVista LLC purchased a new position in shares of MaxCyte during the 4th quarter valued at $70,000. Finally, SG Americas Securities LLC grew its position in shares of MaxCyte by 28.6% during the 4th quarter. SG Americas Securities LLC now owns 48,550 shares of the company’s stock valued at $228,000 after purchasing an additional 10,800 shares in the last quarter. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on MXCT shares. Stephens restated an “overweight” rating and set a $11.00 price target on shares of MaxCyte in a research report on Tuesday, April 23rd. William Blair reaffirmed an “outperform” rating on shares of MaxCyte in a report on Wednesday, March 13th. Finally, BTIG Research dropped their price objective on shares of MaxCyte from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, March 13th.

Check Out Our Latest Stock Analysis on MXCT

MaxCyte Trading Up 10.1 %

MXCT stock opened at $4.05 on Tuesday. The firm’s 50-day moving average price is $4.38 and its two-hundred day moving average price is $4.48. MaxCyte, Inc. has a 12-month low of $2.45 and a 12-month high of $5.55. The stock has a market capitalization of $424.52 million, a price-to-earnings ratio of -11.57 and a beta of 1.41.

MaxCyte (NASDAQ:MXCTGet Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. MaxCyte had a negative net margin of 83.00% and a negative return on equity of 15.68%. The firm had revenue of $11.34 million for the quarter, compared to analysts’ expectations of $7.75 million. Equities analysts predict that MaxCyte, Inc. will post -0.5 EPS for the current year.

Insider Activity at MaxCyte

In related news, CEO Maher Masoud purchased 29,557 shares of MaxCyte stock in a transaction that occurred on Friday, June 7th. The shares were bought at an average price of $4.87 per share, for a total transaction of $143,942.59. Following the completion of the transaction, the chief executive officer now directly owns 29,557 shares of the company’s stock, valued at $143,942.59. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other MaxCyte news, Director John Joseph Johnston sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $3.99, for a total value of $39,900.00. Following the sale, the director now owns 141,950 shares in the company, valued at $566,380.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Maher Masoud acquired 29,557 shares of the business’s stock in a transaction on Friday, June 7th. The stock was acquired at an average price of $4.87 per share, for a total transaction of $143,942.59. Following the acquisition, the chief executive officer now owns 29,557 shares of the company’s stock, valued at approximately $143,942.59. The disclosure for this purchase can be found here. 3.00% of the stock is owned by corporate insiders.

MaxCyte Company Profile

(Free Report)

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Read More

Institutional Ownership by Quarter for MaxCyte (NASDAQ:MXCT)

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.